-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ASH Clinical Practice Guidelines on Amyloidosis

Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Plasma Cell Disorders, Chronic Myeloid Malignancies, Diseases, Myeloid Malignancies
Sunday, December 8, 2024: 4:30 PM-6:00 PM
Grand Hall B (Manchester Grand Hyatt San Diego)
Chair:
Vishal Kukreti, MD, MSc, Princess Margaret Cancer Centre
Disclosures:
No relevant conflicts of interest to declare.

This session will review the scope and goals of the upcoming guidelines on amyloidosis, and will provide insights on risk factors, selecting a target site versus a surrogate site for diagnostic biopsies, and using Congo Red stain screening.
Increasing Awareness of Risk Factors for AL Amyloidosis

Joselle Cook, MBBS

Mayo, Rochester, MN
Target Site vs. Surrogate Site Biopsy for Diagnosis

Angela Dispenzieri, MD

Mayo Clinic, Rochester, MN
Target Site Vs. Surrogate Site Biopsy for Diagnosis

Hira Shaikh, MD

University of Iowa Caver College of Medicine, Coralville, IA
Congo Red Stain Bone Marrow Screening for AL Amyloidosis

Naresh Bumma, MD

The Ohio State University, Columbus, OH
See more of: Special-Interest Sessions
<< Previous Session | Next Session >>